More than 1,500 Xarelto lawsuits have been filed in state and federal litigations on behalf of patients who allegedly suffered internal bleeding, strokes, blood clots and other serious complications related to its use. The rapid growth in claims coincides with the adoption of new filing procedures in the U.S. District Court, Eastern District of Louisiana, where the majority of claims involving the new-generation blood thinner have been filed.
The Eastern District of Louisiana is home to just over 1,230 Xarelto filings. The cases are all part of a multidistrict litigation that was established last year to allow all federal lawsuits involving the medication to undergo coordinated pretrial proceedings. The Court is now allowing Xarelto lawyers to file bundled complaints in the litigation, resulting in its substantial growth over the last several weeks. On August 3rd alone, four bundled cases were filed, with each naming between 11 and 89 plaintiffs. The complaints included several wrongful death claims, and involved allegations of various Xarelto bleeding injuries including gastrointestinal bleeding, hematuria, subdural hematoma, and cerebral hemorrhaging.
A second consolidated litigation underway in the Philadelphia Court of Common Pleas includes 367 Xarelto lawsuits. According to a report from The Legal Intelligencer, the Xarelto mass tort ranks among the Court’s fastest growing litigations.
All of the Xarelto lawsuits pending in these proceedings accuse the drug’s manufacturers of failing to provide patients and doctors with adequate warnings regarding the potential for uncontrollable internal bleeding and related complications. Plaintiffs also allege that Xarelto was wrongly marketed as being superior to warfarin, a blood thinner that has been in use for decades. Among other things, the lawsuits point out that while internal bleeding associated with warfarin can be stopped via the administration of vitamin K, there currently exists no approved antidote to reverse Xarelto bleeding.
Xarelto is a new-generation anticoagulant that was approved by the U.S. Food & Drug Administration in 2011. The drug’s label includes a black box warning that contains information about the increased risk of blood clot formation after premature discontinuation of the medication in the absence of adequate alternative anticoagulation.
Bernstein Liebhard LLP is now representing a number of Xarelto lawsuits plaintiffs, and our attorneys continue to review cases on behalf of others who may have been harmed by this drug. To learn more, please call .